Undergraduate education

University of Kansas, BS, 2006

Years in MSTP



Clinical investigation, 2012


Paul Sondel, MD, PhD

Thesis title

Preclinical and clinical development of intratumorally administered HU14.18-IL2 as treatment for neuroblastoma and melanoma: The importance of tumor infiltrating leukocytes in tumors treated with HU14.18-IL2


Pathology, University of Wisconsin-Madison, School of Medicine and Public Health, 2014-2018


Selective Cancer Biomarker and Molecular Genetic Pathology, MD Anderson Cancer Center, University of Texas, 2018-

Current position

Fellow, Department of Pathology, University of Texas - Houston, MD Anderson Cancer Center

Undergraduate and/or masters publications

Graham DW, Trippett C, Dodds WK, O'Brien JM, Banner EB, Head IM, Smith MS, Yang RK, Knapp CW. Correlations between in situ denitrification activity and nir-gene abundances in pristine and impacted prairie streams. Environ Pollut. 2010 Oct;158(10):3225-9. PMID: 20724046; PMCID: PMC3071025.

Peak N, Knapp CW, Yang RK, Hanfelt MM, Smith MS, Aga DS, Graham DW. Abundance of six tetracycline resistance genes in wastewater lagoons at cattle feedlots with different antibiotic use strategies. Environ Microbiol. 2007 Jan;9(1):143-51. PMID: 17227419.

Smith MS, Yang RK, Knapp CW, Niu Y, Peak N, Hanfelt MM, Galland JC, Graham DW. Quantification of tetracycline resistance genes in feedlot lagoons by real-time PCR. Appl Environ Microbiol. 2004 Dec;70(12):7372-7. PMID: 15574938; PMCID: PMC535139.

PhD publications

Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res. 2016 Jul 1;76(13):3929-41. PMID: 27197149; PMCID: PMC4930687.

Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40. PMID: 23211623; PMCID: PMC3521848.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention. J Immunol. 2012 Sep 1;189(5):2656-64. PMID: 22844125; PMCID: PMC3424361.

Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. 2012 Mar 6. PMID: 22392192; PMCID: PMC3572779.

Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2011 Sep;57(3):398-405. PMID: 21681921; PMCID: PMC3172052.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8. PMID: 21340652; PMCID: PMC3094716.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61. PMID: 20935224; PMCID: PMC2999644.

Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future. 2010;35(8):665. PMID: 21037966; PMCID: PMC2964668.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. PMID: 23661160; PMCID: PMC3720701.

Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018 Oct;67(10):1647-1658. PMID: 30073390; PMCID: PMC6168354.